EMA Recommends Granting a Conditional Marketing Authorisation for Loncastuximab Tesirine
The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the medicinal product loncastuximab tesirine (Zynlonta), intended for the treatment of adult patients with diffuse large B-cell lymphoma and high-grade B-cell lymphoma.
The applicant for this medicinal product is ADC Therapeutics (NL) B.V.




















